相似文献
1
The in-vivo metabolism of C3 in ankylosing spondylitis.
Ann Rheum Dis. 1982 Feb;41(1):86-9. doi: 10.1136/ard.41.1.86.
2
Serum complement and immunoglobulin levels in sporadic and familial ankylosing spondylitis.
J Rheumatol. 1975 Sep;2(3):308-13.
3
Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis.
J Lab Clin Med. 1976 Sep;88(3):427-39.
4
[Circulating immune complexes-like material and complement in rheumatoid arthritis and ankylosing spondylitis (author's transl)].
Med Clin (Barc). 1981 Apr 25;76(8):339-46.
5
[Functional abnormalities of complement in familial and sporadic ankylosing spondylitis].
Arch Invest Med (Mex). 1989 Jan-Mar;20(1):79-86.
6
C3 metabolism in ulcerative colitis and Crohn's disease.
Clin Exp Immunol. 1977 Jun;28(3):490-5.
7
Circulating immune complexes in patients with ankylosing spondylitis.
Ann Rheum Dis. 1980 Oct;39(5):445-8. doi: 10.1136/ard.39.5.445.
8
[Serum complement in rheumatoid disease and ankylosing spondylitis. Study of the clinical forms, clinical stages and sex occurrence].
Rev Hosp Clin Fac Med Sao Paulo. 1974 Nov-Dec;29(6):318-21.
9
Detection & characterization of immune complexes in the sera of ankylosing spondylitis patients.
Indian J Med Res. 1985 Nov;82:447-51.
10
Metabolic studies of C3 in man.
J Immunol Methods. 1979;30(1):69-75. doi: 10.1016/0022-1759(79)90274-6.
引用本文的文献
1
The complement factor H-related protein-5 (CFHR5) exacerbates pathological bone formation in ankylosing spondylitis.
J Mol Med (Berl). 2024 Apr;102(4):571-583. doi: 10.1007/s00109-024-02428-6. Epub 2024 Feb 29.
2
A Potential New Mouse Model of Axial Spondyloarthritis Involving the Complement System.
Immune Netw. 2021 Dec 15;21(6):e45. doi: 10.4110/in.2021.21.e45. eCollection 2021 Dec.
3
Inhibition of Complement Retards Ankylosing Spondylitis Progression.
Sci Rep. 2016 Oct 4;6:34643. doi: 10.1038/srep34643.
4
A multilectin affinity approach for comparative glycoprotein profiling of rheumatoid arthritis and spondyloarthropathy.
Clin Proteomics. 2013 Sep 6;10(1):11. doi: 10.1186/1559-0275-10-11.
5
Immunological variables and acute-phase reactants in patients with ankylosing spondylitis (Bechterew's syndrome) and their relatives.
Clin Rheumatol. 1984 Dec;3(4):501-13. doi: 10.1007/BF02031273.
6
Production of tumour necrosis factor and interleukin 1 by monocytes of patients with previous Yersinia arthritis.
Clin Exp Immunol. 1988 Jun;72(3):410-4.
本文引用的文献
1
The theory of tracer experiments with 131I-labelled plasma proteins.
Phys Med Biol. 1957 Jul;2(1):36-53. doi: 10.1088/0031-9155/2/1/305.
2
Aseptic isolation of human complement component C3 for in vivo studies.
Scand J Clin Lab Invest. 1980 Sep;40(5):487-9. doi: 10.3109/00365518009101873.
3
The metabolism of C3 in adult coeliac disease.
Scand J Gastroenterol. 1980;15(1):33-8. doi: 10.3109/00365528009181428.
4
Metabolism of the third component of complement (C3) in patients with rheumatoid arthritis.
Arthritis Rheum. 1972 Jan-Feb;15(1):49-56. doi: 10.1002/art.1780150108.
5
Immunochemical quantitation of antigens by single radial immunodiffusion.
Immunochemistry. 1965 Sep;2(3):235-54. doi: 10.1016/0019-2791(65)90004-2.
6
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.
J Clin Invest. 1974 Jun;53(6):1578-87. doi: 10.1172/JCI107708.
7
Complement metabolism in the seronegative arthritides.
Ann Rheum Dis. 1974 Nov;33(6):495-9. doi: 10.1136/ard.33.6.495.
8
Serum complement and immunoglobulin levels in sporadic and familial ankylosing spondylitis.
J Rheumatol. 1975 Sep;2(3):308-13.
9
Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis.
J Lab Clin Med. 1976 Sep;88(3):427-39.
10
C3 metabolism in ulcerative colitis and Crohn's disease.
Clin Exp Immunol. 1977 Jun;28(3):490-5.
Zotero 插件